Retrospective baseline biomarker analyses in a first-in-human Phase 1 trial of the PKMYT1 inhibitor lunresertib (RP-6306) in pts with advanced solid tumors harboring CCNE1 amplification and/or deleterious alterations in FBXW7 or PPP2R1A

被引：0
|
作者：
Aguado-Fraile, Elia
Sethuraman, Sunantha
Petrone, Adam
Bacque, Emeline
Schram, Alison
Lheureux, Stephanie
Lee, Elizabeth K.
Koehler, Maria
Silverman, Ian M.
Rimkunas, Victoria
Yap, Timothy A.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-B169
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B169
引用
收藏
页数：2
相关论文
共 25 条
  • [1] MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A
    Yap, Timothy A.
    Schram, Alison
    Lee, Elizabeth K.
    Simpkins, Fiona
    Weiss, Mia C.
    LoRusso, Patricia
    Hojgaard, Martin
    Carneiro, Benedito A.
    Moy, Ryan H.
    Garrido-Laguna, Ignacio
    Koehler, Maria
    Unger, Thaddeus J.
    Bacque, Emeline
    Aguado-Fraile, Elia
    Sethuraman, Sunantha
    Dhake, Snehal
    Liu, Yajun
    Fretland, Adrian J.
    Sun, Xizi
    Xu, Yi
    Hawkey, Nathan
    Truong, Jen
    Lheureux, Stephanie
    [J]. MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [2] First-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors harboring cancer-associated gene alterations
    Yap, Timothy A.
    Miller, Crystal
    Stenehjem, David
    Brown, Eric J.
    Carleton, Mike
    Mirza, Nadeem Q.
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [3] First-in-human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors
    Simpkins, Fiona
    Mahipal, Amit
    LoRusso, Patricia
    Schneider, Reva
    Miller, Crystal
    Stenehjem, David
    Brown, Eric J.
    Carleton, Mike
    Gullbo, Joachim
    Mirza, Nadeem Q.
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [4] Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ACSS2, in patients with advanced solid tumors.
    Perets, Ruth
    Geva, Ravit
    McKean, Meredith
    Goutopoulos, Andreas
    Erez, Omri
    Phadnis, Monica
    Youssoufian, Hagop
    Schwartz, Brian E.
    Kansra, Vikram
    Fattaey, Ali
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor-resistant advanced solid tumors
    Patel, Manish R.
    Juric, Dejan
    Henick, Brian S.
    Moore, Kathleen N.
    Do, Doreen
    Chapman, Joshua
    Zhang, Hui
    Roche, Maria
    Newberry, Kate J.
    Rinne, Mikael
    Yap, Timothy A.
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [6] First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors.
    Shimizu, Toshio
    Doi, Toshihiko
    Kondo, Shunsuke
    Takahashi, Hideaki
    Yamamoto, Noboru
    Sheldon-Waniga, Emily
    Zhou, Xiaofei
    Bahamon, Brittany
    Li, Hongmei
    Kuboki, Yasutoshi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] First-in-human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations
    Yap, Timothy
    Lee, Elizabeth
    Spigel, David
    Fontana, Elisa
    Hojgaard, Martin
    Lheureux, Stephanie
    Mettu, Niharika B.
    Carter, Louise
    Plummer, Ruth
    Ulanet, Danielle
    Manley, Peter
    Jiang, Ying
    Rosen, Ezra
    [J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [8] First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors.
    Yap, Timothy A.
    Dumbrava, Ecaterina Elena
    Ahnert, Jordi Rodon
    Hong, David S.
    Pant, Shubham
    Karp, Daniel D.
    Piha-Paul, Sarina Anne Anne
    Subbiah, Vivek
    Tsimberidou, Apostolia Maria
    Fu, Siqing
    Janku, Filip
    Montez, Sandra
    Ahmad-Taha, Majd T.
    Guerrero, Darlene
    Nazarenko, Natalya N.
    Moore, Yan
    Soth, Michael
    Kovacs, Jeff
    Heffernan, Timothy P.
    Jones, Philip
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET
    Hong, D.
    Bazhenova, L.
    Cho, B. C.
    Sen, S.
    Ponz-Sarvise, M.
    Heist, R.
    Zimmerman, Z.
    Le, X.
    Xuan, D.
    Junming, Z.
    Lee, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 138 : S1 - S1
  • [10] VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor (CDK4/6i)-resistant advanced solid tumors
    Yap, Timothy
    Patel, Manish
    Henick, Brian
    Moore, Kathleen
    Leary, Alexandra
    Do, Doreen
    Chapman, Josh
    Zhang, Hui
    Roche, Maria
    Newberry, Kate
    Rinne, Mikael
    Juric, Dejan
    [J]. GYNECOLOGIC ONCOLOGY, 2023, 176 : S173 - S173
123